Clinical Trial Update: Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib in combination with BKM120 in advanced non-small cell lung cancer patients previously sensitive to erlotinib; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BKM120 (Buparlisib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-12-13